Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 77

1.

CSF1R inhibitors exhibit antitumor activity in acute myeloid leukemia by blocking paracrine signals from support cells.

Edwards DK 5th, Watanabe-Smith K, Rofelty A, Damnernsawad A, Laderas T, Lamble A, Lind EF, Kaempf A, Mori M, Rosenberg M, d'Almeida A, Long N, Agarwal A, Sweeney DT, Loriaux M, McWeeney SK, Tyner JW.

Blood. 2019 Feb 7;133(6):588-599. doi: 10.1182/blood-2018-03-838946. Epub 2018 Nov 13.

PMID:
30425048
2.

Functional genomic landscape of acute myeloid leukaemia.

Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL, Long N, Schultz AR, Traer E, Abel M, Agarwal A, Blucher A, Borate U, Bryant J, Burke R, Carlos A, Carpenter R, Carroll J, Chang BH, Coblentz C, d'Almeida A, Cook R, Danilov A, Dao KT, Degnin M, Devine D, Dibb J, Edwards DK 5th, Eide CA, English I, Glover J, Henson R, Ho H, Jemal A, Johnson K, Johnson R, Junio B, Kaempf A, Leonard J, Lin C, Liu SQ, Lo P, Loriaux MM, Luty S, Macey T, MacManiman J, Martinez J, Mori M, Nelson D, Nichols C, Peters J, Ramsdill J, Rofelty A, Schuff R, Searles R, Segerdell E, Smith RL, Spurgeon SE, Sweeney T, Thapa A, Visser C, Wagner J, Watanabe-Smith K, Werth K, Wolf J, White L, Yates A, Zhang H, Cogle CR, Collins RH, Connolly DC, Deininger MW, Drusbosky L, Hourigan CS, Jordan CT, Kropf P, Lin TL, Martinez ME, Medeiros BC, Pallapati RR, Pollyea DA, Swords RT, Watts JM, Weir SJ, Wiest DL, Winters RM, McWeeney SK, Druker BJ.

Nature. 2018 Oct;562(7728):526-531. doi: 10.1038/s41586-018-0623-z. Epub 2018 Oct 17.

3.

Synthetic lethality of TNK2 inhibition in PTPN11-mutant leukemia.

Jenkins C, Luty SB, Maxson JE, Eide CA, Abel ML, Togiai C, Nemecek ER, Bottomly D, McWeeney SK, Wilmot B, Loriaux M, Chang BH, Tyner JW.

Sci Signal. 2018 Jul 17;11(539). pii: eaao5617. doi: 10.1126/scisignal.aao5617.

4.

Targeting of colony-stimulating factor 1 receptor (CSF1R) in the CLL microenvironment yields antineoplastic activity in primary patient samples.

Edwards V DK, Sweeney DT, Ho H, Eide CA, Rofelty A, Agarwal A, Liu SQ, Danilov AV, Lee P, Chantry D, McWeeney SK, Druker BJ, Tyner JW, Spurgeon SE, Loriaux MM.

Oncotarget. 2018 May 15;9(37):24576-24589. doi: 10.18632/oncotarget.25191. eCollection 2018 May 15.

5.

SYK inhibition thwarts the BAFF - B-cell receptor crosstalk and thereby antagonizes Mcl-1 in chronic lymphocytic leukemia.

Paiva C, Rowland TA, Sreekantham B, Godbersen C, Best SR, Kaur P, Loriaux MM, Spurgeon SEF, Danilova OV, Danilov AV.

Haematologica. 2017 Nov;102(11):1890-1900. doi: 10.3324/haematol.2017.170571. Epub 2017 Aug 24.

6.

Double autophagy stimulation using chemotherapy and mTOR inhibition combined with hydroxychloroquine for autophagy modulation in patients with relapsed or refractory multiple myeloma.

Scott EC, Maziarz RT, Spurgeon SE, Medvedova E, Gajewski J, Reasor-Heard S, Park B, Kratz A, Thomas GV, Loriaux M, Cascio M, Podolak J, Gordon M, Botelho J, Stadtmauer E, Amaravadi R, Vogl DT.

Haematologica. 2017 Jul;102(7):e261-e265. doi: 10.3324/haematol.2016.162321. Epub 2017 Apr 6. No abstract available.

7.

CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation.

Gordon MJ, Tardi P, Loriaux MM, Spurgeon SE, Traer E, Kovacsovics T, Mayer LD, Tyner JW.

Leuk Res. 2017 Feb;53:39-49. doi: 10.1016/j.leukres.2016.12.002. Epub 2016 Dec 12.

PMID:
28013106
8.

Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia.

Leonard JT, Rowley JS, Eide CA, Traer E, Hayes-Lattin B, Loriaux M, Spurgeon SE, Druker BJ, Tyner JW, Chang BH.

Sci Transl Med. 2016 Aug 31;8(354):354ra114. doi: 10.1126/scitranslmed.aaf5309.

PMID:
27582059
9.

The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618I.

Maxson JE, Luty SB, MacManiman JD, Paik JC, Gotlib J, Greenberg P, Bahamadi S, Savage SL, Abel ML, Eide CA, Loriaux MM, Stevens EA, Tyner JW.

Clin Cancer Res. 2016 Feb 1;22(3):757-64. doi: 10.1158/1078-0432.CCR-14-3100. Epub 2015 Oct 16.

10.

Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma.

Siegel MB, Liu SQ, Davare MA, Spurgeon SE, Loriaux MM, Druker BJ, Scott EC, Tyner JW.

Oncotarget. 2015 Aug 7;6(22):18921-32.

11.

Coordinate regulation of residual bone marrow function by paracrine trafficking of AML exosomes.

Huan J, Hornick NI, Goloviznina NA, Kamimae-Lanning AN, David LL, Wilmarth PA, Mori T, Chevillet JR, Narla A, Roberts CT Jr, Loriaux MM, Chang BH, Kurre P.

Leukemia. 2015 Dec;29(12):2285-95. doi: 10.1038/leu.2015.163. Epub 2015 Jun 25.

12.

Alterations in acute myeloid leukaemia bone marrow stromal cell exosome content coincide with gains in tyrosine kinase inhibitor resistance.

Viola S, Traer E, Huan J, Hornick NI, Tyner JW, Agarwal A, Loriaux M, Johnstone B, Kurre P.

Br J Haematol. 2016 Mar;172(6):983-6. doi: 10.1111/bjh.13551. Epub 2015 Jun 11. No abstract available.

13.

Therapeutically Targetable ALK Mutations in Leukemia.

Maxson JE, Davare MA, Luty SB, Eide CA, Chang BH, Loriaux MM, Tognon CE, Bottomly D, Wilmot B, McWeeney SK, Druker BJ, Tyner JW.

Cancer Res. 2015 Jun 1;75(11):2146-50. doi: 10.1158/0008-5472.CAN-14-1576.

14.

YM155 potently kills acute lymphoblastic leukemia cells through activation of the DNA damage pathway.

Chang BH, Johnson K, LaTocha D, Rowley JS, Bryant J, Burke R, Smith RL, Loriaux M, Müschen M, Mullighan C, Druker BJ, Tyner JW.

J Hematol Oncol. 2015 Apr 22;8:39. doi: 10.1186/s13045-015-0132-6.

15.

Disruption of IKAROS activity in primitive chronic-phase CML cells mimics myeloid disease progression.

Beer PA, Knapp DJ, Miller PH, Kannan N, Sloma I, Heel K, Babovic S, Bulaeva E, Rabu G, Terry J, Druker BJ, Loriaux MM, Loeb KR, Radich JP, Erber WN, Eaves CJ.

Blood. 2015 Jan 15;125(3):504-15. doi: 10.1182/blood-2014-06-581173. Epub 2014 Nov 4.

16.

BCR-ABL1 promotes leukemia by converting p27 into a cytoplasmic oncoprotein.

Agarwal A, Mackenzie RJ, Besson A, Jeng S, Carey A, LaTocha DH, Fleischman AG, Duquesnes N, Eide CA, Vasudevan KB, Loriaux MM, Firpo E, Cortes JE, McWeeney S, O'Hare T, Roberts JM, Druker BJ, Deininger MW.

Blood. 2014 Nov 20;124(22):3260-73. doi: 10.1182/blood-2013-04-497040. Epub 2014 Oct 7.

17.

A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor.

Burke RT, Meadows S, Loriaux MM, Currie KS, Mitchell SA, Maciejewski P, Clarke AS, Dipaolo JA, Druker BJ, Lannutti BJ, Spurgeon SE.

Oncotarget. 2014 Feb 28;5(4):908-15.

18.

Comparison of methods to identify aberrant expression patterns in individual patients: augmenting our toolkit for precision medicine.

Bottomly D, Ryabinin PA, Tyner JW, Chang BH, Loriaux MM, Druker BJ, McWeeney SK, Wilmot B.

Genome Med. 2013 Nov 29;5(11):103. doi: 10.1186/gm509. eCollection 2013.

19.

The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition.

Fleischman AG, Maxson JE, Luty SB, Agarwal A, Royer LR, Abel ML, MacManiman JD, Loriaux MM, Druker BJ, Tyner JW.

Blood. 2013 Nov 21;122(22):3628-31. doi: 10.1182/blood-2013-06-509976. Epub 2013 Sep 30.

20.

CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway.

Prins RC, Burke RT, Tyner JW, Druker BJ, Loriaux MM, Spurgeon SE.

Leukemia. 2013 Oct;27(10):2094-6. doi: 10.1038/leu.2013.228. Epub 2013 Jul 31. No abstract available.

PMID:
23900138
21.

Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.

Maxson JE, Gotlib J, Pollyea DA, Fleischman AG, Agarwal A, Eide CA, Bottomly D, Wilmot B, McWeeney SK, Tognon CE, Pond JB, Collins RH, Goueli B, Oh ST, Deininger MW, Chang BH, Loriaux MM, Druker BJ, Tyner JW.

N Engl J Med. 2013 May 9;368(19):1781-90. doi: 10.1056/NEJMoa1214514.

22.

Imatinib and Dasatinib Inhibit Hemangiosarcoma and Implicate PDGFR-β and Src in Tumor Growth.

Dickerson EB, Marley K, Edris W, Tyner JW, Schalk V, Macdonald V, Loriaux M, Druker BJ, Helfand SC.

Transl Oncol. 2013 Apr;6(2):158-68. Epub 2013 Apr 1.

23.

A case study of personalized therapy for osteosarcoma.

Davis LE, Hofmann NE, Li G, Huang ET, Loriaux MM, Bracha S, Helfand SC, Mata JE, Marley K, Mansoor A, Tyner JW, Abraham J, Séguin B, Keller C.

Pediatr Blood Cancer. 2013 Aug;60(8):1313-9. doi: 10.1002/pbc.24512. Epub 2013 Mar 22.

PMID:
23526721
24.

HitWalker: variant prioritization for personalized functional cancer genomics.

Bottomly D, Wilmot B, Tyner JW, Eide CA, Loriaux MM, Druker BJ, McWeeney SK.

Bioinformatics. 2013 Feb 15;29(4):509-10. doi: 10.1093/bioinformatics/btt003. Epub 2013 Jan 9.

25.

The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia.

Spurgeon SE, Coffey G, Fletcher LB, Burke R, Tyner JW, Druker BJ, Betz A, DeGuzman F, Pak Y, Baker D, Pandey A, Hollenbach SJ, Sinha U, Loriaux MM.

J Pharmacol Exp Ther. 2013 Feb;344(2):378-87. doi: 10.1124/jpet.112.200832. Epub 2012 Dec 7.

26.

Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia.

Bicocca VT, Chang BH, Masouleh BK, Muschen M, Loriaux MM, Druker BJ, Tyner JW.

Cancer Cell. 2012 Nov 13;22(5):656-67. doi: 10.1016/j.ccr.2012.08.027.

27.

Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening.

Tyner JW, Yang WF, Bankhead A 3rd, Fan G, Fletcher LB, Bryant J, Glover JM, Chang BH, Spurgeon SE, Fleming WH, Kovacsovics T, Gotlib JR, Oh ST, Deininger MW, Zwaan CM, Den Boer ML, van den Heuvel-Eibrink MM, O'Hare T, Druker BJ, Loriaux MM.

Cancer Res. 2013 Jan 1;73(1):285-96. doi: 10.1158/0008-5472.CAN-12-1906. Epub 2012 Oct 18.

28.

An adaptive Src-PDGFRA-Raf axis in rhabdomyosarcoma.

Abraham J, Chua YX, Glover JM, Tyner JW, Loriaux MM, Kilcoyne A, Giles FJ, Nelon LD, Carew JS, Ouyang Y, Michalek JE, Pal R, Druker BJ, Rubin BP, Keller C.

Biochem Biophys Res Commun. 2012 Sep 28;426(3):363-8. doi: 10.1016/j.bbrc.2012.08.092. Epub 2012 Aug 30.

29.

Effects of plerixafor in combination with BCR-ABL kinase inhibition in a murine model of CML.

Agarwal A, Fleischman AG, Petersen CL, MacKenzie R, Luty S, Loriaux M, Druker BJ, Woltjer RL, Deininger MW.

Blood. 2012 Sep 27;120(13):2658-68. Epub 2012 Aug 13.

30.

Creation of fibrinogen-enhanced experimental blood clots to evaluate mechanical thrombectomy devices for treatment of acute stroke: an in vitro study.

Luo ZH, Chung A, Choi G, Lin YH, Uchida BT, Pavcnik D, Loriaux MM, Nesbit GM, Keller FS, Rösch J.

J Vasc Interv Radiol. 2012 Aug;23(8):1077-83. doi: 10.1016/j.jvir.2012.04.031. Epub 2012 Jun 26.

PMID:
22739646
31.

Multiplex high-throughput gene mutation analysis in acute myeloid leukemia.

Dunlap J, Beadling C, Warrick A, Neff T, Fleming WH, Loriaux M, Heinrich MC, Kovacsovics T, Kelemen K, Leeborg N, Gatter K, Braziel RM, Press R, Corless CL, Fan G.

Hum Pathol. 2012 Dec;43(12):2167-76. doi: 10.1016/j.humpath.2012.03.002. Epub 2012 Jun 1.

PMID:
22658276
32.

Newly described activating JAK3 mutations in T-cell acute lymphoblastic leukemia.

Bains T, Heinrich MC, Loriaux MM, Beadling C, Nelson D, Warrick A, Neff TL, Tyner JW, Dunlap J, Corless CL, Fan G.

Leukemia. 2012 Sep;26(9):2144-6. doi: 10.1038/leu.2012.74. Epub 2012 Mar 19. No abstract available.

PMID:
22425895
33.

TSLP signaling network revealed by SILAC-based phosphoproteomics.

Zhong J, Kim MS, Chaerkady R, Wu X, Huang TC, Getnet D, Mitchell CJ, Palapetta SM, Sharma J, O'Meally RN, Cole RN, Yoda A, Moritz A, Loriaux MM, Rush J, Weinstock DM, Tyner JW, Pandey A.

Mol Cell Proteomics. 2012 Jun;11(6):M112.017764. doi: 10.1074/mcp.M112.017764. Epub 2012 Feb 16.

34.

In vitro sensitivity to dasatinib in lymphoblasts from a patient with t(17;19)(q22;p13) gene rearrangement pre-B acute lymphoblastic leukemia.

Glover JM, Loriaux M, Tyner JW, Druker BJ, Chang BH.

Pediatr Blood Cancer. 2012 Sep;59(3):576-9. doi: 10.1002/pbc.23383. Epub 2011 Oct 28.

35.

TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms.

Fleischman AG, Aichberger KJ, Luty SB, Bumm TG, Petersen CL, Doratotaj S, Vasudevan KB, LaTocha DH, Yang F, Press RD, Loriaux MM, Pahl HL, Silver RT, Agarwal A, O'Hare T, Druker BJ, Bagby GC, Deininger MW.

Blood. 2011 Dec 8;118(24):6392-8. doi: 10.1182/blood-2011-04-348144. Epub 2011 Aug 22.

36.

Survey of activated FLT3 signaling in leukemia.

Gu TL, Nardone J, Wang Y, Loriaux M, Villén J, Beausoleil S, Tucker M, Kornhauser J, Ren J, MacNeill J, Gygi SP, Druker BJ, Heinrich MC, Rush J, Polakiewicz RD.

PLoS One. 2011 Apr 28;6(4):e19169. doi: 10.1371/journal.pone.0019169.

37.

Association of JAK2 mutation status and cytogenetic abnormalities in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms.

Dunlap J, Kelemen K, Leeborg N, Braziel R, Olson S, Press R, Huang J, Gatter K, Loriaux M, Fan G.

Am J Clin Pathol. 2011 May;135(5):709-19. doi: 10.1309/AJCPS6C8EVYCQNRM.

PMID:
21502425
38.

Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies.

Gozgit JM, Wong MJ, Wardwell S, Tyner JW, Loriaux MM, Mohemmad QK, Narasimhan NI, Shakespeare WC, Wang F, Druker BJ, Clackson T, Rivera VM.

Mol Cancer Ther. 2011 Jun;10(6):1028-35. doi: 10.1158/1535-7163.MCT-10-1044. Epub 2011 Apr 11.

39.

Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity.

Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ.

J Clin Invest. 2011 Jan;121(1):396-409. doi: 10.1172/JCI35721. Epub 2010 Dec 13. Erratum in: J Clin Invest. 2011 Mar 1;121(3):1222.

40.

CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability.

Lannutti BJ, Meadows SA, Herman SE, Kashishian A, Steiner B, Johnson AJ, Byrd JC, Tyner JW, Loriaux MM, Deininger M, Druker BJ, Puri KD, Ulrich RG, Giese NA.

Blood. 2011 Jan 13;117(2):591-4. doi: 10.1182/blood-2010-03-275305. Epub 2010 Oct 19.

41.

MET receptor sequence variants R970C and T992I lack transforming capacity.

Tyner JW, Fletcher LB, Wang EQ, Yang WF, Rutenberg-Schoenberg ML, Beadling C, Mori M, Heinrich MC, Deininger MW, Druker BJ, Loriaux MM.

Cancer Res. 2010 Aug 1;70(15):6233-7. doi: 10.1158/0008-5472.CAN-10-0429.

42.

CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms.

Tyner JW, Bumm TG, Deininger J, Wood L, Aichberger KJ, Loriaux MM, Druker BJ, Burns CJ, Fantino E, Deininger MW.

Blood. 2010 Jun 24;115(25):5232-40. doi: 10.1182/blood-2009-05-223727. Epub 2010 Apr 12.

43.

Small intestinal submucosa plug for closure of dilated nephrostomy tracts: a pilot study in swine.

Kakizawa H, Conlin MJ, Pavcnik D, Uchida BT, Loriaux M, Kim YH, Keller FS, Rösch J.

Cardiovasc Intervent Radiol. 2010 Jun;33(3):596-600. doi: 10.1007/s00270-010-9811-4. Epub 2010 Jan 29.

PMID:
20112022
44.

AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.

O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, Adrian LT, Zhou T, Huang WS, Xu Q, Metcalf CA 3rd, Tyner JW, Loriaux MM, Corbin AS, Wardwell S, Ning Y, Keats JA, Wang Y, Sundaramoorthi R, Thomas M, Zhou D, Snodgrass J, Commodore L, Sawyer TK, Dalgarno DC, Deininger MW, Druker BJ, Clackson T.

Cancer Cell. 2009 Nov 6;16(5):401-12. doi: 10.1016/j.ccr.2009.09.028.

45.

A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib.

McWeeney SK, Pemberton LC, Loriaux MM, Vartanian K, Willis SG, Yochum G, Wilmot B, Turpaz Y, Pillai R, Druker BJ, Snead JL, MacPartlin M, O'Brien SG, Melo JV, Lange T, Harrington CA, Deininger MW.

Blood. 2010 Jan 14;115(2):315-25. doi: 10.1182/blood-2009-03-210732. Epub 2009 Oct 16.

46.

A BCR-ABL mutant lacking direct binding sites for the GRB2, CBL and CRKL adapter proteins fails to induce leukemia in mice.

Johnson KJ, Griswold IJ, O'Hare T, Corbin AS, Loriaux M, Deininger MW, Druker BJ.

PLoS One. 2009 Oct 13;4(10):e7439. doi: 10.1371/journal.pone.0007439.

47.

Thrombus formation after percutaneous catheterization and manual compression of the femoral artery in heparinized sheep.

Kim YH, Pavcnik D, Kakizawa H, Uchida BT, Burke A, Loriaux M, Keller FS, Rosch J.

Cardiovasc Intervent Radiol. 2010 Apr;33(2):321-9. doi: 10.1007/s00270-009-9688-2. Epub 2009 Aug 25.

PMID:
19705199
48.

RNAi screen for rapid therapeutic target identification in leukemia patients.

Tyner JW, Deininger MW, Loriaux MM, Chang BH, Gotlib JR, Willis SG, Erickson H, Kovacsovics T, O'Hare T, Heinrich MC, Druker BJ.

Proc Natl Acad Sci U S A. 2009 May 26;106(21):8695-700. doi: 10.1073/pnas.0903233106. Epub 2009 May 11.

49.

Functional characterization of an activating TEK mutation in acute myeloid leukemia: a cellular context-dependent activating mutation.

Tyner JW, Rutenberg-Schoenberg ML, Erickson H, Willis SG, O'Hare T, Deininger MW, Druker BJ, Loriaux MM.

Leukemia. 2009 Jul;23(7):1345-8. doi: 10.1038/leu.2009.66. Epub 2009 Apr 2. No abstract available.

PMID:
19340004
50.

Multicentric castleman disease with ocular involvement: a clinicopathologic case report.

Emerson GG, Lim L, Loriaux M, Yassin HM, Flaxel CJ, Smith JR, Wilson DJ.

Retin Cases Brief Rep. 2009 Spring;3(2):197-9. doi: 10.1097/ICB.0b013e3181658ca8.

PMID:
25391074

Supplemental Content

Loading ...
Support Center